Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians

DESCRIPTION The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease. METHODS This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library. Literature was reassessed in April 2013, and additional studies were included. Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events. The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease. This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system. RECOMMENDATION 1 ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease. (Grade: weak recommendation; low-quality evidence) RECOMMENDATION 2 ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease. (Grade: strong recommendation; moderate-quality evidence).

[1]  J. Gardin,et al.  Blood Transfusion and In‐hospital Outcomes in Anemic Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention , 2007, Clinical cardiology.

[2]  G. Fonarow,et al.  Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). , 2011, The American journal of cardiology.

[3]  G. Filippatos,et al.  Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[4]  D. Silverberg,et al.  Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. , 2006, American heart journal.

[5]  P. Armstrong,et al.  Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. , 2009, European heart journal.

[6]  A. Jacobs,et al.  Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: Data from the National Heart, Lung, and Blood Institute Dynamic Registry , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  Bruce Leff,et al.  Informing Clinical Practice Guideline Development and Implementation: Prevalence of Coexisting Conditions Among Adults with Coronary Heart Disease , 2011, Journal of the American Geriatrics Society.

[8]  E. Topol,et al.  Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. , 2009, JACC. Cardiovascular interventions.

[9]  M. Kruszewski,et al.  Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. , 2008, European heart journal.

[10]  R. Califf,et al.  A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. , 2010, Kidney international.

[11]  B. Chaitman,et al.  Liberal or restrictive transfusion in high-risk patients after hip surgery. , 2011, The New England journal of medicine.

[12]  M. Bell,et al.  Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. , 2008, JACC. Cardiovascular interventions.

[13]  N. Weissman,et al.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.

[14]  M. Zahid,et al.  Impact of blood transfusions in patients presenting with anemia and suspected acute coronary syndrome. , 2007, The American journal of cardiology.

[15]  H. Krumholz,et al.  Blood transfusion in elderly patients with acute myocardial infarction. , 2001, The New England journal of medicine.

[16]  J. Comín-Colet,et al.  A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. , 2009, Journal of cardiac failure.

[17]  Akshay S. Desai,et al.  Treatment of anemia with darbepoetin alfa in systolic heart failure. , 2013, The New England journal of medicine.

[18]  Michele Tarsilla Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[19]  H. Uno,et al.  Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  D. Mancini,et al.  Effect of erythropoietin on exercise capacity in anemic patients with advanced heart failure. , 2003, Kidney international. Supplement.

[21]  Sunil V. Rao,et al.  The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. , 2005, Journal of the American College of Cardiology.

[22]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[23]  P. Armstrong,et al.  Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia , 2008, Circulation.

[24]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[25]  J. Marshall,et al.  Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? , 2001, Critical care medicine.

[26]  W. Markiewicz,et al.  Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. , 2008, The American journal of cardiology.

[27]  Regina M. Hardison,et al.  Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. , 2013, American heart journal.

[28]  Sunil V. Rao,et al.  Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). , 2011, The American journal of cardiology.

[29]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[30]  J. Panza,et al.  Does the relation between red blood cell transfusion and mortality vary according to transfusion indication? A case–control study among patients with acute coronary syndromes , 2011, Coronary artery disease.

[31]  T. Osler,et al.  Association between Intraoperative Blood Transfusion and Mortality and Morbidity in Patients Undergoing Noncardiac Surgery , 2011, Anesthesiology.

[32]  D. Kansagara,et al.  Treatment of Anemia in Patients With Heart Disease , 2013, Annals of Internal Medicine.

[33]  P. Ponikowski,et al.  Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. , 2007, Journal of the American College of Cardiology.

[34]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[35]  Sunil V. Rao,et al.  Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. , 2008, American heart journal.

[36]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[37]  P. Shekelle,et al.  The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods , 2010, Annals of Internal Medicine.

[38]  A. Nissenson,et al.  The normal hematocrit study--follow-up. , 2008, The New England journal of medicine.

[39]  V. Boyko,et al.  Blood transfusion for acute decompensated heart failure--friend or foe? , 2009, American heart journal.

[40]  J. J. Griffin,et al.  Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. , 2009, JACC. Cardiovascular interventions.

[41]  J. Boura,et al.  Impact of Acute Blood Loss Anemia and Red Blood Cell Transfusion on Mortality after Percutaneous Coronary Intervention , 2007, Clinical cardiology.

[42]  A. Jaffe,et al.  Perioperative red blood cell transfusion and outcome in stable patients after elective major vascular surgery. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[43]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[44]  P. Poole‐Wilson,et al.  The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. , 2006, European heart journal.

[45]  J. Magaziner,et al.  A pilot randomized trial comparing symptomatic vs. hemoglobin‐level‐ driven red blood cell transfusions following hip fracture , 1998, Transfusion.

[46]  C. Schorr,et al.  Risk of cardiac arrhythmias and conduction abnormalities in patients with acute myocardial infarction receiving packed red blood cell transfusions. , 2011, Journal of critical care.

[47]  D. Silverberg,et al.  Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. , 2007, American heart journal.

[48]  J. Duguid,et al.  Guidelines for the clinical use of red cell transfusions , 2001, British journal of haematology.

[49]  D. Silverberg,et al.  β-Erythropoietin Effects on Ventricular Remodeling, Left and Right Systolic Function, Pulmonary Pressure, and Hospitalizations in Patients Affected With Heart Failure and Anemia , 2009, Journal of cardiovascular pharmacology.

[50]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[51]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2007, Journal of the American College of Cardiology.

[52]  P. Duarte,et al.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.

[53]  R. Giugliano,et al.  Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.

[54]  J. Małyszko,et al.  Prevalence of chronic kidney disease and anemia in patients with coronary artery disease with normal serum creatinine undergoing percutaneous coronary interventions: relation to New York Heart Association class. , 2010, The Israel Medical Association journal : IMAJ.

[55]  Harlan M Krumholz,et al.  The prognostic importance of anemia in patients with heart failure. , 2003, The American journal of medicine.

[56]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[57]  Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians , 2013, Annals of Internal Medicine.

[58]  G. Lemesle,et al.  Value of blood transfusion in patients with a blood hematocrit of 24% to 30% after percutaneous coronary intervention. , 2009, The American journal of cardiology.

[59]  G. Filippatos,et al.  Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2009, The American journal of cardiology.

[60]  G. Filippatos,et al.  Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2008, American heart journal.

[61]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[62]  J D Hilton,et al.  Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) , 2008, Heart.

[63]  C. O'connor,et al.  Anemia as a risk factor and therapeutic target in heart failure. , 2004, Journal of the American College of Cardiology.

[64]  W. Pevec,et al.  A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. , 1997, American journal of surgery.